RESULTS OF CLINICAL STUDY OF RUSSIAN BIOANALOGUE FOR INTERFERON-BETA-1b



Cite item

Full Text

Abstract

There were presented results of many-sided perspective randomized comparative clinical study of Russian preparation Interferon-Beta-1b - ronbetal and of original preparation Betaferon. During 7,5 months of taking of these preparations there was conducted a monthly magnetic resonance tomography together with intravenous injection of paramagnetic contrast agent. This clinical investigation has demonstrated equal safety, tolerance and effectiveness of Ronbetal and Interferon.

About the authors

Еkaterina Vadimovna Baidina

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Аlexei Nikolaevich Boyko

1) Russian State Medical University of the Russian Health Ministry,2) Моscow city centre of Multiple Sclerosis on the base of city clinical hospital №11

1) Russian State Medical University of the Russian Health Ministry,2) Моscow city centre of Multiple Sclerosis on the base of city clinical hospital №11

Vasily Valerjevich Brukhov

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Еvgeny Ivanovich Gusev

1) Russian State Medical University of the Russian Health Ministry,2) Моscow city centre of Multiple Sclerosis on the base of city clinical hospital №11

1) Russian State Medical University of the Russian Health Ministry,2) Моscow city centre of Multiple Sclerosis on the base of city clinical hospital №11

Lubov Vladimirovna Dubchak

Clinic of nervous diseases, named after I.М. Sechenov of Russian Health Ministry

Clinic of nervous diseases, named after I.М. Sechenov of Russian Health Ministry

Igor Alexeevich Zavalishin

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Roman Аlexeevich Ivanov

Biotechnical company "BIOCAD"

Email: ivanov@biocad.ru
Biotechnical company "BIOCAD"

Sergei Vikyorovich Коtov

Moskovsky Regional Research Clinical Institute, named after M.F. Vladimirsky

Moskovsky Regional Research Clinical Institute, named after M.F. Vladimirsky

Маrina Viktorovna Кrotenkova

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Neurology Scientific Centre Of the Russian Academy of Medical Sciences

Veronica Igorevna Par

Biotechnical company "BIOCAD"

Biotechnical company "BIOCAD"

Таtyana Еvgenievna Shmidt

Clinic of nervous diseases, named after I.М. Sechenov of Russian Health Ministry

Clinic of nervous diseases, named after I.М. Sechenov of Russian Health Ministry

Sergei Gennadievich Schur

Моscow city centre of Multiple Sclerosis on the base of city clinical hospital №11

Моscow city centre of Multiple Sclerosis on the base of city clinical hospital №11

Nikolai Nikolaevich Jahno

Clinic of nervous diseases, named after I.М. Sechenov of Russian Health Ministry

Clinic of nervous diseases, named after I.М. Sechenov of Russian Health Ministry

References

  1. Гусев, Е.И. Современные подходы к использованию бета-интерферонов в лечении рассеянного склероза / Е.И. Гусев, А.Н. Бойко // Журн. неврол. и психиатр. - 2000, -№11. - С. 54-59.
  2. Новик, А.А. Исследование качества жизни в медицине [под ред. Ю.Л. Шевченко] / А.А. Новик, Т.И. Ионова. - М.: ГЭОТАР-МЕД, 2004. - 304 с.
  3. Bayas, A. Managing the Adverse Effects of Interferon-в Therapy in Multiple Sclerosis / A. Bayas, P. Reickmann // Drug. Safety. - 2000. - Vol. 22. - P. 149-159.
  4. Durelli, L. Every-one-day interferon-beta-1b versus once-weekly interferon-beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN) / L. Durelli, E. Verdun, P. Barbero et al. // Lancet. - 2002. - Vol. 27. - P. 1453-1460.
  5. ЕМЕА. The rules governing medicinal products in the European Union. Investigation of Bioavailability and Bioequivalence. - 1998. - Vol. 3C. - P. 231-244.
  6. European Study Group on Interferon-b-1b in Secondary Progressive MA. Placebo-controlled multicentre randomised trial of interferon-b-1b in treatment of secondary progressive multiple sclerosis (by Ludwig Kappos) // Lancet. - 1998. - Vol. 352. - P. 1491-1497.
  7. Gaines, A.R. Interferon beta-1b injection site reactions and necrosis / A.R .Gaines, F. Varrichio// Multiple Sclerosis. - 1998. - Vol. 4. - P. 70-73.
  8. Goodkin, D.E. CA and the North American Study Group on Interferon-beta-1b in Secondary Progressive MS. Interferon-beta-1b in Secondary Progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract no.LBN.004]. /52th Annual Meeting of the American Academy of Neurology Late Breakers; 2000 Apr 29 - May 6, San Diego, USA. режим доступа: http//www.fda.gov/cder/biologics/review/ifnbchi 031403r2.pdf.
  9. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS; final outcome of the randomized controlled trial // Neurology. - 1995. - Vol. 45. - P. 1277-1285.
  10. IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial // Neurology. - 1993. - Vol. 43. - P. 655-661.
  11. Lublin, F.D. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference / F.D. Lublin, J.N. Whitaker, B.H. Eidelman et al. // Neurology. - 1996. - Vol. 46. - P. 12-18.
  12. Lyseng-Williamson, KA. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis / K.A. Lyseng-Williamson, D. Murdoch // Drugs. - 2005. - Vol. 65(9). - P. 1295-312.
  13. Miller, D.H. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis / D.H. Miller, P.D. Molyneux, G.J. Barker et al. // Ann. Neurol. - 1999 Dec. - Vol. 46(6). - P. 850-859.
  14. Mohr, D.C. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment / D.C. Mohr, D.E. Goodkin, W. Likosky et al. // Multiple Sclerosis. - 1996. - Vol. 2. - P. 222-226.
  15. Munschauer, F.E. Managing side effects of Interferon-beta in patients with relapsing-remitting multiple sclerosis / F.E. Munschauer, R.P. Kinkel // Clin. Therap.- 1997. - Vol. 19. - P. 883-893.
  16. Paty, D.W. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines / D.W. Paty, H.P. Hartung, G.C. Ebers et al. // Eur J. Neurol. - 1999. - Vol. 6 (Suppi 1). - P. 1-35.
  17. Paty, D.W. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. The UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group / D.W. Paty, D.K. Li // Neurology. - 1993. - Vol. 43. - P. 662-667.
  18. Rice, G.P. et al. Ibuprofen treatment versus gradual introduction of interferon в-1b in patient with MS // Neurology. - 1999. - Vol. 52(9). - P. 1893-1895.
  19. Rudick, R.A. Treatment of multiple sclerosis with type I interferons. / R.A. Rudick, W. Sibley, L. Durelli / In: Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. - Springer-Verlag, London, 1996. - P. 230-231.
  20. Walther, E.U. Managment of side effects of beta-interferon therapy in MS / E.U. Walther, T. Dang, R. Hohlfeld // Int. MS J. - 1999. - Vol. 5. - P. 65-70.
  21. Walther, E.U. Multiple sclerosis. Side effects of interferon beta therapy and their management / E.U. Walther, R. Hohlfeld // Neurology. - 1999. - Vol. 53. - P. 1622-1633.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Baidina Е.V., Boyko А.N., Brukhov V.V., Gusev Е.I., Dubchak L.V., Zavalishin I.A., Ivanov R.А., Коtov S.V., Кrotenkova М.V., Par V.I., Shmidt Т.Е., Schur S.G., Jahno N.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.